The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
FlexiTubes will showcase range of eco-friendly and innovative tube options
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Subscribe To Our Newsletter & Stay Updated
